

Product Datasheet

Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal NB600-1159

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Reviews: 2 Publications: 76

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB600-1159

Updated 10/23/2024 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NB600-1159



NB600-1159

Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal

Product Information	
Unit Size	0.1 mg
Concentration	1.0 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Monoclonal
Clone	114C307.1
Preservative	0.05% Sodium Azide
Isotype	IgG1 Kappa
Purity	Protein G purified
Buffer	PBS
Target Molecular Weight	14.96 kDa

Product Description	
Host	Mouse
Gene ID	5366
Gene Symbol	PMAIP1
Species	Human, Mouse, Rat
Reactivity Notes	Reactivity in rat is reported in scientific literature (Seda et al Hepatol Res. 2010, 40: 701-710). Rat reactivity reported in scientific literature (PMID:33031904).
Specificity/Sensitivity	An ~80 kD background band may also be seen in Jurkat cell lysate.
Immunogen	This Noxa antibody was developed by immunizing mice with a fusion protein containing human Noxa.


Product Application Details	
Applications	Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin
Recommended Dilutions	Western Blot 1-2 ug/ml, Flow Cytometry 1 ug / million cells, Immunohistochemistry 1:10-1:500, Immunocytochemistry/ Immunofluorescence 1:20-1:1000, Immunohistochemistry-Paraffin 5 ug/ml

Images


Western Blot: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Western blot analysis in RL-7 cells (a follicular lymphoma).




Immunocytochemistry/Immunofluorescence: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - ICC/IF analysis using the azide-free version of NB600-1159 at 1:10. HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Image objective 40X.




Immunohistochemistry-Paraffin: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Bouin-fixed, paraffin-embedded Chronic Lymphocytic Leukemia (CLL) xenograft stained with Noxa antibody (1:2000), peroxidase-conjugate and DAB chromogen. Staining for 2 hr at RT. Image using the azide-free form of this antibody.




Flow Cytometry: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Flow cytometry after an intracellular stain was performed on MCF7 cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.




Western Blot: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Western blot analysis in RL-7 cells (a follicular lymphoma).




Western Blot: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Doc counteracts the ABT-737-mediated increase in Mcl-1 protein. Western blot showing treatment of LNCaP and PC3 cells with 1 μ M ABT-737. In LNCaP and PC3, there are few difference in Noxa. Image collected and cropped by CiteAb from the following publication (<https://peerj.com/articles/144>), licensed under a CC-BY license.




Immunohistochemistry-Paraffin: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Bouin-fixed, paraffin-embedded Chronic Lymphocytic Leukemia (CLL) xenograft stained with Noxa antibody (1:2000), peroxidase-conjugate and DAB chromogen. Staining for 2 hr at RT. Image using the azide-free form of this antibody.




Flow Cytometry: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Flow cytometry after an intracellular stain was performed on HeLa cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 μ g/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.




Flow Cytometry: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Flow cytometry after an intracellular stain was performed on MCF7 cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 μ g/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.




Flow Cytometry: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - An intracellular stain was performed on Ntera2 cells with Noxa Antibody [114C307.1] NB600-1159 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).




Flow Cytometry: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - An intracellular stain was performed on Ntera2 cells with Noxa Antibody [114C307.1] NB600-1159 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).




Flow Cytometry: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Flow cytometry after an intracellular stain was performed on HeLa cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.




Doc counteracts the ABT-737-mediated increase in Mcl-1 protein. Western blot showing that treatment of LNCaP and PC3 cells with 1 μ M ABT-737 (A) increases Mcl-1 but treatment with 1 nM Doc (D) decreases Mcl-1. Combination of Doc + ABT-737 (DA) decreases Mcl-1. In LNCaP, there is less Bcl-2 (D, 24 h) and Bak (DA, 48 h) but few differences in Bcl-xL, Bax, Bid, and Noxa. In PC3, there are few differences in Bcl-2, Bcl-xL, Bax, Bak, Bid, and Noxa.



Western Blot: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - Doc counteracts the ABT-737-mediated increase in Mcl-1 protein. Western blot showing that treatment of LNCaP & PC3 cells with 1 μ M ABT-737 (A) increases Mcl-1 but treatment with 1 nM Doc (D) decreases Mcl-1. Combination of Doc + ABT-737 (DA) decreases Mcl-1. In LNCaP, there is less Bcl-2 (D, 24 h) & Bak (DA, 48 h) but few differences in Bcl-xL, Bax, Bid, & Noxa. In PC3, there are few differences in Bcl-2, Bcl-xL, Bax, Bak, Bid, & Noxa. Image collected & cropped by CiteAb from the following publication (<https://peerj.com/articles/144>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: Noxa Antibody (114C307.1) - Non-Recombinant Monoclonal [NB600-1159] - EGb761 regulates Bcl-2 family proteins expression in melanoma cells. (A) EGb761 alters the expression levels of anti- & pro-apoptotic Bcl-2 family proteins in melanoma cell lines. Whole cell lysates from Mel-RM & Mel-AT cells treated with EGb761 (400 μ g/ml) for indicated time periods were subjected to Western blot analysis. The data shown are representative of three individual experiments. (B) 5% ethanol as control vehicle did not alter the expression levels of Mcl-1. Mel-AT cells with 5% ethanol for increasing periods. Whole cell lysates from Mel-AT cells treated were subjected to Western blot analysis. The data shown are representative of three individual experiments. (C) Mel-RM & Mel-AT cells were treated with EGb761 (400 μ g/ml) or 5% ethanol for the indicated periods. Total RNA was isolated & subjected to real-time PCR analysis for Mcl-1. The relative abundance of mRNA expression treated with 5% ethanol was arbitrarily designated as 1. Columns, mean of three individual experiments; bars, SEM. * Present $p < 0.05$ vs control. (D) Relative expression of anti-apoptosis Bcl-2 family proteins in melanoma cell lines Mel-RM & Mel-AT without treatment. Quantitative expression levels of Mcl-1, Bcl-2 & Bcl-XL were normalized to GAPDH. (E) Relative expression of pro-apoptosis Bcl-2 family proteins in melanoma cell lines Mel-RM & Mel-AT without treatment. Quantitative expression levels of Bax, Bid, Noxa, PUMA, Bim, Bad & Bak were normalized to GAPDH. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/25860257>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Hao Liu, Zhenzhan Zhang, Peilin Zhen, Meijuan Zhou High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling Journal of Immunology Research 2021-01-08 [PMID: 33506057]

Al Shboul S, El-Sadoni M, Alhesa A et al. NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy Sci Rep 2023-09-23 [PMID: 37741850] (Immunohistochemistry)

Asuzu DT, Alvarez R, Fletcher PA Et al. Pituitary adenomas evade apoptosis via noxa deregulation in Cushing's disease Cell Rep 2022-08-24 [PMID: 36001971] (IHC-P, Human)

Details:

Citation using the Alexa Fluor 532 version of this antibody.

Dewson G, Huang AS, San Chin H, Reljic B E3 ubiquitin ligase MARCHF5 controls BAK apoptotic activity independently of BH3-only proteins bioRxiv 2022-01-01 [PMID: 36171332] (WB, Human)

Zheng J, Zhuo L, Ran D et al. Cadmium induces apoptosis via generating reactive oxygen species to activate mitochondrial p53 pathway in primary rat osteoblasts *Toxicology* 2020-10-08 [PMID: 33031904] (WB, Rat)

Details:

Citation using the Non-Recombinant Monoclonal format of this antibody.

Tseng HY, Dreyer J, Emran AA et al. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma *Int J Cancer* 2020-04-07 [PMID: 32249419]

Details:

Citation using the Non-Recombinant Monoclonal format of this antibody.

Djajawi TM, Liu L, Gong JN et al. MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex *Cell Death Differ* 2020-02-26 [PMID: 32094511] (WB, Mouse)

Details:

Citation using the Non-Recombinant Monoclonal format of this antibody.

Zall H, Weber A, Besch R et al. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1 *Mol Cancer* 2010-06-26 [PMID: 20576107] (WB)

Details:

Citation using the Non-Recombinant Monoclonal and Biotin format of this antibody.

Pilling AB, Hwang C. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide *Prostate* 2019-06-23 [PMID: 31228231] (WB, Human)

Details:

Citation using the Non-Recombinant Monoclonal format of this antibody.

Gallagher SJ, Gunatilake D, Beaumont KA et al. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma *Int J Cancer* 2017-12-07 [PMID: 29210065] (WB, Human)

Details:

Citation using the Non-Recombinant Monoclonal format of this antibody.

Gonzalez PS, O'Prey J, Cardaci S et al. Mannose impairs tumour growth and enhances chemotherapy *Nature* 2018-11-23 [PMID: 30464341] (Mouse)

Details:

Citation using the Non-Recombinant Monoclonal format of this antibody.

Minieri V, De Dominicis M, Porazzi P et al. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia *Cancer Res* 2018-08-30 [PMID: 30154155] (WB, Human)

Details:

Citation using the Non-Recombinant Monoclonal format of this antibody.

More publications at <http://www.novusbio.com/NB600-1159>



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NB600-1159

NBL1-14534	Noxa Overexpression Lysate
HAF007	Goat anti-Mouse IgG Secondary Antibody [HRP]
NB720-B	Rabbit anti-Mouse IgG (H+L) Secondary Antibody [Biotin]
NBP1-43319-0.5mg	Mouse IgG1 Kappa Isotype Control (P3.6.2.8.1)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB600-1159

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

